EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Preventive effect of R ikkunshito, a traditional J apanese medicine, on chemotherapy‐induced nausea and vomiting with cisplatin: C ase series

Shinya Kajiura, Ayumu Hosokawa, Hiroki Yoshita, Akira Ueda, Takayuki Ando, Haruka Fujinami, Jun Nishikawa, Kohei Ogawa, Toshiro Sugiyama

Traditional & Kampo Medicine · 2015

DOI: 10.1002/tkm2.1012 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Aim Supportive therapies are important to treat chemotherapy‐induced nausea and vomiting ( CINV ). Rikkunshito, a Kampo medicine, has been reported to be effective against cisplatin‐induced anorexia in rats. In the present study, we evaluated the preventive effect of Rikkunshito for CINV in patients receiving high‐dose cisplatin chemotherapy. Methods We selected patients who received chemotherapy including cisplatin (≥60 mg/m 2 ) for gastric or esophageal cancer between April 2010 and August 2012. We identified 20 patients treated without a reduction in the dose of anticancer medications during the second course and added 7.5 g/day Rikkunshito, which was orally administered, for 7 days. All patients were treated with 5‐hydroxytryptamine‐3 receptor antagonist, corticosteroid, and neurokinin‐1 receptor antagonist for the prevention of CINV during the first and second courses. We evaluated complete response ( CR ; defined as no emesis and no rescue medication) and other toxicities according to the Common Terminology Criteria for Adverse Events version 4.0. Results The median patient age was 63 years (range, 49–77 years). The chemotherapy regimens used were cisplatin plus 5‐fluorouracil in 15 patients with esophageal cancer and cisplatin plus S‐1 in five patients with gastric cancer. Rate of delayed CR was 75.0% during the first course (95% CI : 56.0–94.0%), which improved during the second course to 95.0% (95% CI : 85.4–100%, P = 0.077). There was no significant difference in other major toxicities between the first and second courses. Conclusion Rikkunshito has the potential to alleviate CINV in patients receiving high‐dose cisplatin chemotherapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →